| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
20,240,000 |
| Market
Cap: |
9.21(M) |
| Last
Volume: |
34,981 |
Avg
Vol: |
34,885 |
| 52
Week Range: |
$0.455 - $0.455 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Chembio Diagnostics develops and commercializes point-of-care diagnostic tests used for the detection and diagnosis of infectious diseases, including sexually transmitted disease and COVID-19. Co.'s product portfolio is based upon its proprietary DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, and drugs of abuse. The DPP technology platform can provide sensitivity and specificity, multiplexing capabilities, and with the DPP Micro Reader, quantitative results.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,490,120 |
| Total Buy Value |
$0 |
$0 |
$0 |
$663,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
13 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Davis Katherine Lyon |
|
• • – |
2019-05-06 |
4 |
D |
$7.15 |
$163,123 |
D/D |
(22,800) |
90,143 |
|
- |
|
| Davis Katherine Lyon |
|
• • – |
2019-05-06 |
4 |
OE |
$3.48 |
$163,125 |
D/D |
46,875 |
112,943 |
|
- |
|
| Potthoff John Gary |
|
• • – |
2018-11-14 |
4 |
B |
$5.80 |
$116,150 |
D/D |
20,000 |
27,772 |
0.01 |
- |
|
| Passas Robert |
See Remarks |
• • – |
2018-11-05 |
4 |
B |
$6.75 |
$101,250 |
D/D |
15,000 |
15,000 |
0.01 |
- |
|
| Gyorke David |
See Remarks |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
20,725 |
20,725 |
|
- |
|
| Page Gail S |
|
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,772 |
7,772 |
|
- |
|
| Sperzel John J Iii |
See Remarks |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
98,446 |
98,446 |
|
- |
|
| Davis Katherine Lyon |
|
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,772 |
66,068 |
|
- |
|
| Klugewicz Sharon W |
See Remarks |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
20,725 |
39,436 |
|
- |
|
| Goldman Neil A |
See Remarks |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
31,088 |
45,903 |
|
- |
|
| Polan Mary Lake Ph D |
|
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,772 |
7,772 |
|
- |
|
| Esfandiari Javan |
See Remarks |
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
38,860 |
138,773 |
|
- |
|
| Potthoff John Gary |
|
• • – |
2018-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,772 |
7,772 |
|
- |
|
| Esfandiari Javan |
Chief Science/Tech Officer |
• • – |
2018-06-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,345) |
99,913 |
|
- |
|
| Esfandiari Javan |
Chief Science/Tech Officer |
• • – |
2018-06-13 |
4 |
OE |
$5.64 |
$112,800 |
D/D |
20,000 |
111,258 |
|
- |
|
| Klugewicz Sharon W |
President, Americas |
• • – |
2018-05-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,737) |
18,711 |
|
- |
|
| Klugewicz Sharon W |
President, Americas |
• • – |
2018-05-16 |
4 |
OE |
$4.50 |
$22,500 |
D/D |
5,000 |
21,448 |
|
- |
|
| Meller Gary |
Director |
– • – |
2018-02-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,272) |
134,603 |
|
- |
|
| Meller Gary |
Director |
– • – |
2018-02-26 |
4 |
OE |
$3.48 |
$128,325 |
D/D |
36,875 |
151,875 |
|
- |
|
| Goldman Neil A |
EVP & Chief Financial Officer |
• – – |
2018-02-13 |
4 |
B |
$6.75 |
$100,001 |
D/D |
14,815 |
14,815 |
2.74 |
- |
|
| Esfandiari Javan |
Chief Science/Tech Officer |
• – – |
2018-01-16 |
4 |
D |
$8.67 |
$328,746 |
D/D |
(37,922) |
91,258 |
|
- |
|
| Esfandiari Javan |
Chief Science/Tech Officer |
• – – |
2018-01-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,765 |
129,180 |
|
- |
|
| Klugewicz Sharon W |
President, Americas |
• – – |
2017-08-28 |
4 |
OE |
$4.45 |
$42,044 |
D/D |
9,448 |
16,448 |
|
- |
|
| Meller Gary |
Director |
– • – |
2017-07-13 |
4 |
OE |
$3.48 |
$34,800 |
D/D |
10,000 |
115,000 |
|
- |
|
| Pessin Brian L. |
See Explanation of Responses |
– – – |
2017-06-28 |
4 |
B |
$5.76 |
$35,983 |
D/D |
6,250 |
1,152,317 |
2.44 |
- |
|
120 Records found
|
|
Page 4 of 5 |
|
|
